Myosana Therapeutics, a Seattle, WA-based provider of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, raised $5M in Seed funding.
The round was led by John Ballantyne. New investments from the Muscular Dystrophy Association and Parent Project Muscular Dystrophy (PPMD) rounded out the seed round, building on capital from original investor CureDuchenne Ventures and early investor PPMD a year later.
The company intends to use the funds to support optimization of its platform, moving closer to selection of the first development candidate.
Cofounded by Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., both internationally known experts in neuromuscular disease from the University of Washington, and now led by CEO Dr. Matthew Lumley, Myosana Therapeutics leverages its platform to develop new gene therapies that can potentially transform progressive neuromuscular and cardiac diseases, increasing longevity and improving quality of life. Its first clinical candidate from the platform will be delivery of full-length dystrophin as a therapy for Duchenne muscular dystrophy ( by 2025.)
FinSMEs
25/01/2023